The stock has a 36-month beta value of 0.36. Opinions on the stock are mixed, with 3 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 2 as “sell.”
The public float for TBPH is 43.68M, and at present, short sellers hold a 14.72% of that float. On May 02, 2024, the average trading volume of TBPH was 373.05K shares.
TBPH) stock’s latest price update
The stock price of Theravance Biopharma Inc (NASDAQ: TBPH) has surged by 4.74 when compared to previous closing price of 8.44, but the company has seen a -3.60% decline in its stock price over the last five trading sessions. PRNewsWire reported 2024-04-29 that DUBLIN, April 29, 2024 /PRNewswire/ — Theravance Biopharma, Inc. (NASDAQ: TBPH) will report its first quarter 2024 financial results and provide a business update after market close on Monday, May 13, 2024. An accompanying conference call and simultaneous webcast will be hosted at 5:00 pm ET (2:00 pm PT/10:00 pm IST) that day.
TBPH’s Market Performance
Theravance Biopharma Inc (TBPH) has experienced a -3.60% fall in stock performance for the past week, with a -2.86% drop in the past month, and a -6.75% drop in the past quarter. The volatility ratio for the week is 4.51%, and the volatility levels for the past 30 days are at 4.42% for TBPH. The simple moving average for the last 20 days is -4.94% for TBPH stock, with a simple moving average of -7.94% for the last 200 days.
Analysts’ Opinion of TBPH
Many brokerage firms have already submitted their reports for TBPH stocks, with BTIG Research repeating the rating for TBPH by listing it as a “Buy.” The predicted price for TBPH in the upcoming period, according to BTIG Research is $21 based on the research report published on April 12, 2024 of the current year 2024.
SVB Leerink gave a rating of “Outperform” to TBPH, setting the target price at $12 in the report published on May 23rd of the previous year.
TBPH Trading at -2.55% from the 50-Day Moving Average
After a stumble in the market that brought TBPH to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -26.21% of loss for the given period.
Volatility was left at 4.42%, however, over the last 30 days, the volatility rate increased by 4.51%, as shares sank -4.84% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -0.90% lower at present.
During the last 5 trading sessions, TBPH fell by -3.60%, which changed the moving average for the period of 200-days by -8.11% in comparison to the 20-day moving average, which settled at $9.28. In addition, Theravance Biopharma Inc saw -21.35% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at TBPH starting from Farnum Rhonda, who sale 1,254 shares at the price of $8.71 back on Feb 22 ’24. After this action, Farnum Rhonda now owns 311,733 shares of Theravance Biopharma Inc, valued at $10,922 using the latest closing price.
Farnum Rhonda, the SVP, COMM & MEDICAL AFFAIRS of Theravance Biopharma Inc, sale 1,378 shares at $10.29 during a trade that took place back on Nov 21 ’23, which means that Farnum Rhonda is holding 331,206 shares at $14,180 based on the most recent closing price.
Stock Fundamentals for TBPH
Current profitability levels for the company are sitting at:
- -0.98 for the present operating margin
- 0.85 for the gross margin
The net margin for Theravance Biopharma Inc stands at -0.96. The total capital return value is set at -0.16. Equity return is now at value -16.86, with -11.16 for asset returns.
Based on Theravance Biopharma Inc (TBPH), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -0.55. The debt to equity ratio resting at 0.23. The interest coverage ratio of the stock is -23.85.
Currently, EBITDA for the company is -40.28 million with net debt to EBITDA at -0.13. When we switch over and look at the enterprise to sales, we see a ratio of 7.51. The receivables turnover for the company is 3.29for trailing twelve months and the total asset turnover is 0.15. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.39.
Conclusion
To sum up, Theravance Biopharma Inc (TBPH) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
